Relay Therapeutics Inc (NASDAQ: RLAY) has seen a rise in its stock price by 6.71 in relation to its previous close of 7.60. However, the company has experienced a -14.72% decline in its stock price over the last five trading sessions. fool.com reported 2024-09-11 that The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
Company’s 36-month beta value is 1.62.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RLAY is 111.73M, and currently, short sellers hold a 8.11% ratio of that floaft. The average trading volume of RLAY on September 16, 2024 was 1.81M shares.
RLAY’s Market Performance
RLAY’s stock has seen a -14.72% decrease for the week, with a 21.59% rise in the past month and a 10.94% gain in the past quarter. The volatility ratio for the week is 18.53%, and the volatility levels for the past 30 days are at 9.61% for Relay Therapeutics Inc The simple moving average for the past 20 days is 12.40% for RLAY’s stock, with a -1.49% simple moving average for the past 200 days.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Buy.” The predicted price for RLAY in the upcoming period, according to Jefferies is $16 based on the research report published on September 10, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $20. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
RLAY Trading at 7.67% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.20% of loss for the given period.
Volatility was left at 9.61%, however, over the last 30 days, the volatility rate increased by 18.53%, as shares surge +25.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.04% upper at present.
During the last 5 trading sessions, RLAY fell by -15.04%, which changed the moving average for the period of 200-days by -0.98% in comparison to the 20-day moving average, which settled at $7.30. In addition, Relay Therapeutics Inc saw -26.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Catinazzo Thomas, who sale 10,780 shares at the price of $8.56 back on Jul 29 ’24. After this action, Catinazzo Thomas now owns 319,650 shares of Relay Therapeutics Inc, valued at $92,316 using the latest closing price.
Rahmer Peter sale 15,128 shares at $8.28 during a trade that took place back on Jul 30 ’24, which means that Rahmer Peter is holding 405,637 shares at $125,260 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -10.51 for the present operating margin
- 0.84 for the gross margin
The net margin for Relay Therapeutics Inc stands at -9.17. The total capital return value is set at -0.51. Equity return is now at value -43.28, with -37.22 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.49. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -53.34.
Currently, EBITDA for the company is -380.57 million with net debt to EBITDA at 0.22. When we switch over and look at the enterprise to sales, we see a ratio of 34.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.64.
Conclusion
In a nutshell, Relay Therapeutics Inc (RLAY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
